Population Genomic Screening Programs Global Market Report 2026

The population genomic screening programs market size has grown rapidly in recent years. It will grow from $3.91 billion in 2025 to $4.47 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to growing awareness of hereditary diseases, implementation of newborn screening programs, advances in sequencing technologies, increasing government health initiatives, rising healthcare infrastructure.

The population genomic screening programs market size is expected to see rapid growth in the next few years. It will grow to $7.7 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to expansion of adult and carrier screening programs, adoption of ai-based genomic interpretation tools, integration with digital health platforms, increasing demand for personalized medicine, investment in population genomic research. Major trends in the forecast period include population-wide genetic risk assessment, integration with electronic health records (ehr), ai-driven variant interpretation, personalized preventive health programs, data security & privacy compliance.

The increasing demand for personalized medicine is anticipated to drive the expansion of the population genomic screening programs market. Personalized medicine refers to the customization of medical treatments and healthcare decisions based on an individual’s genetic, environmental, and lifestyle factors to enhance therapeutic efficacy and safety. The rising adoption of personalized medicine is fueled by advancements in genomics and molecular diagnostics, which allow clinicians to better comprehend genetic differences and provide more precise, targeted therapies that improve patient outcomes and minimize adverse effects. Population genomic screening programs serve as a critical foundation for promoting personalized medicine by detecting genetic variations and disease-related risk factors across extensive and diverse populations. These programs facilitate early detection of disease risks, stratification of patient groups, and the creation of tailored prevention and treatment strategies at both individual and public health levels. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, indicated that in 2023 the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases, up from six approvals in 2022. Consequently, the rising demand for personalized medicine is propelling the growth of the population genomic screening programs market.

Leading companies operating in the population genomic screening programs market are focusing on developing innovative solutions such as, hereditary risk assessment to enable early detection of genetic predispositions, guide personalized prevention strategies, and improve long-term health outcomes. Hereditary risk assessment refers to the evaluation of an individual’s likelihood of developing certain genetic disorders or diseases based on their inherited genetic variants and family medical history. For example, in November 2023, Helix OpCo, LLC, a US-based population genomics and clinical technology company, partnered with Cone Health, a US-based not-for-profit network of healthcare providers, to launch a population genomics initiative to advance precision medicine in North Carolina. This program deploys Helix's end-to-end platform to deliver actionable precision medicine insights, enabling earlier interventions, community wellness efforts, and health equity improvements across Alamance, Forsyth, Guilford, Rockingham, and Randolph counties and beyond.

In August 2024, Natera Inc., a US-based biotechnology company, completed the acquisition of Invitae Corp. for an undisclosed sum. Through this acquisition, Natera seeks to broaden its capabilities in non-invasive prenatal and carrier screening, strengthening its service portfolio and extending support to a larger number of patients and healthcare providers. Invitae Corp. is a US-based medical genetics company that provides population genomic screening programs.

Major companies operating in the population genomic screening programs market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Illumina Inc., Natera Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Fulgent Genetics Inc., Ambry Genetics Corporation, Pacific Biosciences of California Inc., Color Genomics Inc., Helix OpCo Inc., Personalis Inc., CENTOGENE N.V., ProPhase Labs Inc., DNAnexus Inc., Genomics England Limited, Eurofins Genomics Germany GmbH, Sema4 Inc., Mapmygenome India Private Limited, Gencove Inc.

North America was the largest region in the population genomic screening programs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the population genomic screening programs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the population genomic screening programs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The population genomic screening programs market includes revenues earned by entities by providing services such as carrier screening, pharmacogenomic testing, and newborn genomic screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Population genomic screening programs are structured public health initiatives offering genetic testing to large populations, often independent of personal or family history, to detect pathogenic variants linked to actionable health conditions. Their primary aim is early identification of genetic risks, enabling timely prevention, monitoring, or treatment to reduce disease incidence and mortality across communities.

The key program types of population genomic screening programs include newborn screening, adult screening, carrier screening, pharmacogenomics, and other program types. Newborn screening programs aim to identify genetic conditions early in life to enable timely intervention. Program models include national screening programs, regional programs, institution-based screening, and direct-to-consumer screening. Technologies include next-generation sequencing, microarray, polymerase chain reaction, and others. Applications include rare disease detection, cancer risk assessment, pharmacogenomics, chronic disease prediction, and others, serving hospitals, research institutes, government agencies, diagnostic laboratories, and other end users.

Tariffs have affected the population genomic screening market by increasing the cost of importing next-generation sequencing instruments, microarrays, and related reagents. This impact is most pronounced in segments such as newborn and adult screening, particularly in North America and Europe where advanced genomics equipment is often imported. While tariffs pose challenges by raising operational costs, they also encourage local manufacturing and innovation in cost-effective genomic solutions, supporting market resilience and fostering development of domestic capabilities.

The population genomic screening programs market research report is one of a series of new reports that provides population genomic screening programs market statistics, including population genomic screening programs industry global market size, regional shares, competitors with a population genomic screening programs market share, detailed population genomic screening programs market segments, market trends and opportunities, and any further data you may need to thrive in the population genomic screening programs industry. This population genomic screening programs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.